Evidence map›Paper›PMID 33283188›Full record

ReviewNeuroscience insights2020

The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease.

Mahdi Montazer Haghighi, Erfan Ghani Kakhki, Christine Sato, Mahdi Ghani, Ekaterina Rogaeva

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuroscience insights, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Infections withFrontiers in aging neuroscience · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. The relationship of early- and late-onset Alzheimer's disease genes with COVID-19.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mahdi Montazer HaghighiTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Erfan Ghani KakhkiTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Christine SatoTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Mahdi GhaniDisorDATA Analytics, Ottawa, ON, Canada.
Ekaterina RogaevaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-2852-0329
University of Toronto · CA

Funding

Genetic Epidemiology of Early-Onset Alzheimers disease in Caribbean Hispanics and non-Hispanic WhitesRF1AG054080 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BEECHAM, GARY WAYNE, REITZ, CHRISTIANE · 2016 to 2018
$4.0M
NIA NIH HHS RF1 AG054080
6 · The paper itself

Abstract

We reviewed factors that might influence COVID-19 outcomes (eg, neurological symptoms), including the link to Alzheimer's disease. Since the virus triggers COVID-19 infection through binding to ACE2, we focused on the

Indexed as

ACEACE2Alzheimer’s diseaseCOVID-19

Identifiers

PMID33283188
PMCPMC7686598
OpenAlexW3109555043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.